A flurry of congressional activity brings hope of 340B reform. Meanwhile, BIO comments on clinical trial reform. (665 words, 2 minutes, 40 seconds) Congress shows renewed interest in 340B reform ...
Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary. “Dr.
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving ...
LaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement. “The passage of the Mikaela Naylon Give Kids a Chance Act is ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...
We look back on the BIO Patient Advocacy Changemaker Event (PACE) in Washington, D.C.—here’s what we learned. (700 words, 3 minutes, 30 seconds) What we learned at this week’s BIO Patient Advocacy ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results